CoreRx Increases Clinical Manufacturing Capabilities
CoreRx, a leader in early drug contract development, has expanded manufacturing capabilities to include 15-cubic foot and 30-cubic foot V-shell blenders, a 43-station high speed tablet press, high speed encapsulation and a 40-inch solvent-capable coating pan. The additional equipment train will allow for increased clinical batch sizes in support of growing client demand. The additional equipment will allow CoreRx scientists to manufacture batch sizes of up to one million solid dosage units per day.
Combination Products should be considered
According to Pharmaceutical Technology, there has been a surge in the number of combination product (i.e. where a drug product is combined with a medical device) launches in recent years and this trend is set to continue as more companies seek to extend the life of existing branded medicines.
Working together to improve Healthcare
Shorter Path to Drug Discovery share research on failed compounds between companies the new MIT lead approach- Posted on November 18, 2009 by Albin Paul .
The Massachusetts Institute of Technology, have, started a pharmaceutical innovation program to help drug companies adapt some successful approaches now used in aeronautics, like lean management and information-sharing among rivals.

